Biomarkers in endometrial cancer: Possible clinical applications (Review)
Author(s) -
Kouji Banno,
Iori Kisu,
Megumi Yanokura,
Kosuke Tsuji,
Kenta Masuda,
Arisa Ueki,
Yusuke Kobayashi,
Wataru Yamagami,
Hiroyuki Nomura,
Eiichiro Tominaga,
Nobuyuki Susumu,
Daisuke Aoki
Publication year - 2012
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2012.654
Subject(s) - endometrial cancer , cancer , oncogene , biology , dna microarray , microarray , cell cycle , gene , biomarker , molecular medicine , cancer research , endometrium , bioinformatics , oncology , medicine , gene expression , genetics , endocrinology
The number of cases of endometrial cancer has shown a tendency to increase in recent years. Endometrial cancer originates from the endometrium and is classified, based on the development mechanism, into types 1 and 2, which are responsive and non-responsive to estrogen, respectively, and have significantly different gene expression profiles. Studies of genes with abnormal expression in endometrial cancer have identified multiple oncogenes, tumor suppressors, mismatch repair genes, apoptosis-associated genes, levels of hormone receptors and DNA ploidy and aneuploidy as biomarkers of endometrial cancer. The use of these molecules and genes may facilitate accurate diagnosis and prognostic prediction and contribute to individualized treatment. Trials of drugs which target these biomarkers and searches for new biomarkers using cDNA microarrays and RT-qPCR are ongoing and it is likely that these findings can be translated to clinical use.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom